Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
AFMD Stock Summary
In the News

Affimed to Present at the 2023 Jefferies Healthcare Conference
HEIDELBERG, Germany, May 30, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that its Chief Executive Officer, Dr. Adi Hoess, will present at the 2023 Jefferies Healthcare Conference on Wednesday, June 7, 2023 at 8:30 a.m. Eastern Daylight Time / 14:30 Central European Time.

Affimed N.V. (AFMD) Q1 2023 Earnings Call Transcript
Affimed N.V. (NASDAQ:AFMD ) Q1 2023 Earnings Conference Call May 23, 2023 8:30 AM ET Company Participants Alex Fudukidis - Director of Investor Relations Adi Hoess - Chief Executive Officer Andreas Harstrick - Chief Medical Officer Angus Smith - Chief Financial Officer Wolfgang Fischer - Chief Operating Officer Arndt Schottelius - Chief Scientific Officer Conference Call Participants Maurice Raycroft - Jefferies Li Watsek - Cantor Fitzgerald Srikripa Devarakonda - Truist Securities Bradley Canino - Stifel Yale Jen - Laidlaw Yanan Zhu - Wells Fargo Securities Operator Good day, everyone and welcome to Affimed's First Quarter 2023 Earnings and Corporate Update Call.

Affimed N.V. (AFMD) Reports Q1 Loss, Lags Revenue Estimates
Affimed N.V. (AFMD) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.22.

Affimed to Report First Quarter 2023 Financial Results & Corporate Update on May 23, 2023
HEIDELBERG, Germany, May 16, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release first quarter 2023 results and corporate update on Tuesday, May 23, 2023. The Company will host a conference call at 8:30 a.m. EDT / 14:30 CET.

Affimed N.V. (AFMD) Reports Q4 Loss, Tops Revenue Estimates
Affimed N.V. (AFMD) delivered earnings and revenue surprises of -15.79% and 45.75%, respectively, for the quarter ended December 2022.

Affimed to Report Full Year 2022 Financial Results & Corporate Update on March 23, 2023
HEIDELBERG, Germany, March 16, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release full year 2022 results and corporate update on Thursday, March 23, 2023. The Company will host a conference call at 8:30 a.m. EDT / 13:30 CET.

Affimed to Participate in Fireside Chat at the H.C. Wainwright Cell Therapy Virtual Conference
HEIDELBERG, Germany, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today its Chief Executive Officer, Dr. Adi Hoess, will participate in a fireside chat at the H.C. Wainwright Cell Therapy Conference on Tuesday, February 28, 2023, at 8:30 a.m. EST / 14:30 CET.

Affimed to Present at the SVB Securities 2023 Global Biopharma Conference
HEIDELBERG, Germany, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today its Chief Executive Officer, Dr. Adi Hoess, will present at the SVB Securities 2023 Global Biopharma Conference on Tuesday, February 14, 2023 at 2:20 p.m. EST / 20:20 CET.

7 Cheap But Risky Biotech Stocks
Biotech stocks remain depressed, nearly two years into a dip that has seen the SPDR S&P Biotech ETF drop nearly 50%.

Here's Why Affimed N.V. (AFMD) is Poised for a Turnaround After Losing 47.1% in 4 Weeks
Affimed N.V. (AFMD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it.
AFMD Financial details
AFMD Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
Revenue per share | 0.39 | 0.33 | 0.34 | 0.34 | 0.29 | |
Net income per share | -0.32 | -0.5 | -0.5 | -0.48 | -0.6 | |
Operating cash flow per share | 0.82 | -0.45 | -0.23 | -0.72 | -0.74 | |
Free cash flow per share | 0.81 | -0.48 | -0.24 | -0.76 | -0.74 | |
Cash per share | 1.8 | 1.62 | 1.76 | 1.65 | 1.34 | |
Book value per share | 0.66 | 0.6 | 0.86 | 1.14 | 1.07 | |
Tangible book value per share | 0.66 | 0.6 | 0.84 | 1.12 | 1.07 | |
Share holders equity per share | 0.66 | 0.6 | 0.86 | 1.14 | 1.07 | |
Interest debt per share | 0.09 | 0.06 | 0.02 | 0.16 | 0.14 | |
Market cap | 164.4M | 157.14M | 399.19M | 582.47M | 165.33M | |
Enterprise value | 74.34M | 65.09M | 253.63M | 403.53M | -6.76M | |
P/E ratio | -8.44 | -4.86 | -9.65 | -10.13 | -1.92 | |
Price to sales ratio | 6.93 | 7.35 | 14.08 | 14.43 | 4 | |
POCF ratio | 3.33 | -5.41 | -20.58 | -6.73 | -1.58 | |
PFCF ratio | 3.37 | -5.15 | -20.12 | -6.44 | -1.57 | |
P/B Ratio | 4.1 | 4.06 | 5.54 | 4.28 | 1.08 | |
PTB ratio | 4.1 | 4.06 | 5.54 | 4.28 | 1.08 | |
EV to sales | 3.13 | 3.04 | 8.94 | 10 | -0.16 | |
Enterprise value over EBITDA | -4.08 | -2.1 | -7.41 | -6.3 | 0.08 | |
EV to operating cash flow | 1.5 | -2.24 | -13.07 | -4.66 | 0.06 | |
EV to free cash flow | 1.53 | -2.13 | -12.78 | -4.46 | 0.06 | |
Earnings yield | -0.12 | -0.21 | -0.1 | -0.1 | -0.52 | |
Free cash flow yield | 0.3 | -0.19 | -0.05 | -0.16 | -0.64 | |
Debt to equity | 1.9 | 1.91 | 1.44 | 0.66 | 0.31 | |
Debt to assets | 0.65 | 0.66 | 0.59 | 0.4 | 0.24 | |
Net debt to EBITDA | 4.94 | 2.96 | 4.25 | 2.8 | 1.99 | |
Current ratio | 3.01 | 3.01 | 2.25 | 3.2 | 5.66 | |
Interest coverage | -23.06 | -67.03 | -365.45 | -89.93 | -54.06 | |
Income quality | -2.54 | 0.9 | 0.47 | 1.51 | 1.22 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.41 | 0.48 | 0.48 | 0.6 | 0.78 | |
Research and developement to revenue | 1.48 | 2.05 | 1.76 | 2.02 | 2.39 | |
Intangibles to total assets | 0 | 0 | 0.01 | 0.01 | 0 | |
Capex to operating cash flow | -0.01 | 0.05 | 0.02 | 0.04 | 0.01 | |
Capex to revenue | -0.03 | -0.07 | -0.02 | -0.1 | -0.02 | |
Capex to depreciation | -1.79 | -1.63 | -0.39 | -2.89 | -0.24 | |
Stock based compensation to revenue | 0.09 | 0.12 | 0.12 | 0.29 | 0.46 | |
Graham number | 2.19 | 2.61 | 3.1 | 3.51 | 3.82 | |
ROIC | 0.24 | 0.36 | 0.27 | 0.34 | 0.44 | |
Return on tangible assets | -0.17 | -0.29 | -0.24 | -0.26 | -0.43 | |
Graham Net | 0.56 | 0.49 | 0.54 | 0.94 | 1.02 | |
Working capital | 74.04M | 70.73M | 83.77M | 141.85M | 161.42M | |
Tangible asset value | 40.07M | 38.53M | 70.28M | 134.34M | 152.86M | |
Net current asset value | 34.83M | 32.22M | 47.07M | 117.21M | 148.47M | |
Invested capital | 0.12 | 0.08 | 0.02 | 0.14 | 0.12 | |
Average receivables | 1.27M | 1.46M | 1.96M | 3.62M | 3.75M | |
Average payables | 6.8M | 10.05M | 11.03M | 15.13M | 18.97M | |
Average inventory | 250.5K | 278K | 271K | 333.5K | 524.5K | |
Days sales outstanding | 21.98 | 25.29 | 31.39 | 43.48 | 23.8 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 16.61 | 14.43 | 11.63 | 8.39 | 15.33 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.49 | -0.84 | -0.57 | -0.42 | -0.56 | |
Capex per share | -0.01 | -0.02 | -0.01 | -0.03 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-03-31 for Q1
Metric | History | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 |
---|---|---|---|---|---|---|
Revenue per share | 0.06 | 0.05 | 0.1 | 0.08 | 0.03 | |
Net income per share | -0.14 | -0.12 | -0.09 | -0.26 | -0.21 | |
Operating cash flow per share | -0.23 | -0.18 | -0.13 | -0.22 | -0.22 | |
Free cash flow per share | -0.23 | -0.18 | -0.13 | -0.22 | -0.22 | |
Cash per share | 1.38 | 1.61 | 1.49 | 1.34 | 1.04 | |
Book value per share | 0.95 | 1.31 | 1.21 | 1.07 | 0.84 | |
Tangible book value per share | 0.95 | 1.31 | 1.21 | 1.07 | 0.84 | |
Share holders equity per share | 0.95 | 1.31 | 1.21 | 1.07 | 0.84 | |
Interest debt per share | 0.15 | 0.13 | 0.13 | 0.13 | 0.12 | |
Market cap | 488.2M | 391.28M | 312.97M | 165.33M | 102.11M | |
Enterprise value | 336.99M | 172.84M | 108.81M | -6.76M | -37.02M | |
P/E ratio | -7.32 | -5.7 | -5.68 | -1.13 | -0.8 | |
Price to sales ratio | 60.98 | 53.59 | 21.02 | 14.82 | 22.64 | |
POCF ratio | -17.18 | -14.77 | -16.45 | -5.34 | -3.07 | |
PFCF ratio | -17.11 | -14.73 | -16.36 | -5.27 | -3.07 | |
P/B Ratio | 4.16 | 2.03 | 1.73 | 1.08 | 0.82 | |
PTB ratio | 4.16 | 2.03 | 1.73 | 1.08 | 0.82 | |
EV to sales | 42.09 | 23.67 | 7.31 | -0.61 | -8.21 | |
Enterprise value over EBITDA | -20 | -8.1 | -5.81 | 0.24 | 1.21 | |
EV to operating cash flow | -11.86 | -6.53 | -5.72 | 0.22 | 1.11 | |
EV to free cash flow | -11.81 | -6.5 | -5.69 | 0.22 | 1.11 | |
Earnings yield | -0.03 | -0.04 | -0.04 | -0.22 | -0.31 | |
Free cash flow yield | -0.06 | -0.07 | -0.06 | -0.19 | -0.33 | |
Debt to equity | 0.65 | 0.35 | 0.31 | 0.31 | 0.34 | |
Debt to assets | 0.39 | 0.26 | 0.23 | 0.24 | 0.26 | |
Net debt to EBITDA | 8.98 | 10.24 | 10.9 | 6.18 | 4.54 | |
Current ratio | 3.13 | 4.9 | 5.65 | 5.66 | 5.21 | |
Interest coverage | -45.33 | -56.86 | -47.08 | -65.04 | -65.96 | |
Income quality | 1.71 | 1.36 | 1.15 | 0.93 | 1.04 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.88 | 1.15 | 0.54 | 0.77 | 1.52 | |
Research and developement to revenue | 2.3 | 2.85 | 1.75 | 3 | 6.55 | |
Intangibles to total assets | 0.01 | 0.01 | 0.01 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0.01 | 0.01 | 0 | |
Capex to revenue | -0.01 | -0.01 | -0.01 | -0.04 | 0 | |
Capex to depreciation | -0.3 | -0.25 | -0.27 | -0.22 | -0.03 | |
Stock based compensation to revenue | 0.53 | 0.77 | 0.33 | 0.39 | 0.92 | |
Graham number | 1.7 | 1.85 | 1.59 | 2.5 | 2.01 | |
ROIC | 0.11 | 0.08 | 0.07 | 0.17 | 0.19 | |
Return on tangible assets | -0.09 | -0.07 | -0.06 | -0.18 | -0.19 | |
Graham Net | 0.79 | 1.18 | 1.13 | 1.02 | 0.78 | |
Working capital | 123.14M | 202.78M | 189.72M | 161.42M | 132.36M | |
Tangible asset value | 115.84M | 191.27M | 179.55M | 152.86M | 125.04M | |
Net current asset value | 105.1M | 186.71M | 175.25M | 148.47M | 120.93M | |
Invested capital | 0.16 | 0.1 | 0.1 | 0.12 | 0.13 | |
Average receivables | 4.68M | 5.04M | 3.61M | 2.19M | 3.22M | |
Average payables | 16.2M | 13.15M | 13.92M | 17.08M | 19.61M | |
Average inventory | 453K | 528K | 622K | 650.5K | 647.5K | |
Days sales outstanding | 51.12 | 68.09 | 10.22 | 21.75 | 74.67 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 1.76 | 1.32 | 8.8 | 4.14 | 1.21 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.14 | -0.09 | -0.08 | -0.24 | -0.26 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
AFMD Frequently Asked Questions
What is Affimed N.V. stock symbol ?
Affimed N.V. is a DE stock and trading under the symbol AFMD
What is Affimed N.V. stock quote today ?
Affimed N.V. stock price is $0.7192 today.
Is Affimed N.V. stock public?
Yes, Affimed N.V. is a publicly traded company.